INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.06 USD | -0.82% |
|
-1.30% | -15.50% |
| May. 07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
| May. 01 | TD Cowen Adjusts Price Target on Incyte to $80 From $88 | MT |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the Incyte First Quarter...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
2024-05-15
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
53.06
USD
Average target price
73.35
USD
Spread / Average Target
+38.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.50% | 12.01B | |
| -2.61% | 88.47B | |
| +3.55% | 40.71B | |
| -14.40% | 32.43B | |
| +55.89% | 24.28B | |
| -15.96% | 15.52B | |
| -41.29% | 12.17B | |
| -11.75% | 12B | |
| +7.87% | 8.87B | |
| -3.16% | 8.44B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Transcript : Incyte Corporation, Q1 2022 Earnings Call, May 03, 2022